Literature DB >> 15624359

[Tumor marker in primary lung cancer].

Kenji Sugio1, Masakazu Sugaya, Takeshi Hanagiri, Kosei Yasumoto.   

Abstract

Serum tumor markers are non-invasive diagnostic tools for malignant tumor and commonly used for screening of cancer and as an indicator of treatment-effect. In small cell lung cancer, NSE and proGRP are effective markers. In non-small cell lung cancer (NSCLC), CEA, SCC, CYFRA21-1, SLX and CA19-9 are commonly used for screening, and at least one marker among CEA, SCC or CYFRA21-1 is positive in 77% of patients with NSCLC. According to the histological type, the positive rate of CEA and CYFRA21-1 is high in adenocarcinoma patients, and the positive rate of CYFRA21-1 and SCC is high in squamous cell carcinoma patients. This review summarizes the clinical usefulness of tumor markers in primary lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624359     DOI: 10.7888/juoeh.26.473

Source DB:  PubMed          Journal:  J UOEH        ISSN: 0387-821X


  3 in total

1.  Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease.

Authors:  Feng Chen; Xiu-Ying Wang; Xiao-Hong Han; Hai Wang; Jun Qi
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers.

Authors:  Konstantinos Charalabopoulos; Agathi Karakosta; George Bablekos; Christos Golias; Alexandros Charalabopoulos; Eleni Tsanou; Dimitrios Peschos; Leonidas Zoganas; Anna Batistatou
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis.

Authors:  Andrew Kinloch; Verena Tatzer; Robin Wait; David Peston; Karin Lundberg; Phillipe Donatien; David Moyes; Peter C Taylor; Patrick J Venables
Journal:  Arthritis Res Ther       Date:  2005-10-19       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.